PMGC HOLDINGS INC. Share-based Payment Arrangement, Expense
PMGC HOLDINGS INC. (ELAB) reported Share-based Payment Arrangement, Expense of -$19.16 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-03-30
- PMGC HOLDINGS INC. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $10.66K, a 73.12% decline year-over-year.
- PMGC HOLDINGS INC. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $13.18K, a 71.98% decline year-over-year.
- PMGC HOLDINGS INC. share-based payment arrangement, expense for the quarter ending 2025-06-30 was $15.84K.
- PMGC HOLDINGS INC. share-based payment arrangement, expense for the quarter ending 2025-03-31 was -$58.84K, a 206.32% decline year-over-year.
- PMGC HOLDINGS INC. share-based payment arrangement, expense for fiscal 2025 was -$19.16K, a 119.72% decline from fiscal 2024.
- PMGC HOLDINGS INC. share-based payment arrangement, expense for fiscal 2024 was $97.17K, a 80.08% decline from fiscal 2023.
- PMGC HOLDINGS INC. share-based payment arrangement, expense for fiscal 2023 was $487.74K, a 918.11% increase from fiscal 2022.
- PMGC HOLDINGS INC. share-based payment arrangement, expense for fiscal 2022 was $47.91K.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month | Share-based Payment Arrangement, Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $10.66K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $23.84K derived: sum of 2 quarters · filed 2026-03-30 | $39.68K derived: sum of 3 quarters · filed 2026-03-30 | -$19.16K 10-K · filed 2026-03-30 | |
| 2025-09-30 | $13.18K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $29.02K derived: sum of 2 quarters · filed 2025-11-14 | -$29.82K 10-Q · filed 2025-11-14 | $9.83K derived: sum of 4 quarters · filed 2026-03-30 | |
| 2025-06-30 | $15.84K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$43.00K 10-Q · filed 2025-08-13 | -$3.35K derived: sum of 3 quarters · filed 2026-03-30 | $43.69K derived: sum of 4 quarters · filed 2026-03-30 | |
| 2025-03-31 | -$58.84K 10-Q · filed 2025-05-14 | -$19.19K derived: sum of 2 quarters · filed 2026-03-30 | $27.84K derived: sum of 3 quarters · filed 2026-03-30 | -$17.01K derived: sum of 4 quarters · filed 2026-03-30 | |
| 2024-12-31 | $39.65K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $86.68K derived: sum of 2 quarters · filed 2026-03-30 | $41.83K derived: sum of 3 quarters · filed 2026-03-30 | $97.17K 10-K · filed 2026-03-30 | |
| 2024-09-30 | $47.04K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $2.18K derived: sum of 2 quarters · filed 2025-11-14 | $57.52K 10-Q · filed 2025-11-14 | -$346.00M derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-06-30 | -$44.85K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $10.48K 10-Q · filed 2025-08-13 | -$346.05M derived: sum of 3 quarters · filed 2025-08-13 | ||
| 2024-03-31 | $55.34K 10-Q · filed 2025-05-14 | -$346.01M derived: sum of 2 quarters · filed 2025-05-14 | |||
| 2023-12-31 | -$346.06M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $487.74K 10-K · filed 2025-03-28 | $135.95K 10-K · filed 2024-03-29 | ||
| 2023-09-30 | $346.55M 10-Q · filed 2023-12-11 | ||||
| 2023-03-31 | $75.16K 10-Q · filed 2024-05-15 | -$93.98M derived: sum of 2 quarters · filed 2024-05-15 | |||
| 2022-12-31 | -$94.05M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $47.91K 10-K · filed 2024-03-29 | |||
| 2022-09-30 | $94.10M 10-Q · filed 2023-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B |